HOME >> BIOLOGY >> NEWS
Cancer risk clouds gene cures

DESPITE its spectacular achievements, the first successful form of gene therapy will for now be used only as a last resort due to the risk of cancer. And that's not the only bad news. The latest studies suggest that some other gene therapies using different viruses might also trigger cancer.

The Necker Hospital in Paris pioneered the use of gene therapy to cure the severe inherited immune disease called X-SCID. But two of the 11 boys treated have developed leukaemia. Both these cases appear to be due to the corrective gene being inserted near another gene called Lmo2, which helps control cell growth and can contribute to cancer if turned on at the wrong time (New Scientist, 25 January, p 12).

Calculations by Christof von Kalle of the University of Cincinnati College of Medicine in Ohio suggest that rather than being an extraordinary coincidence the engineered mouse retrovirus used to deliver the gene in the French studymay insert it near Lmo2 about once per 100,000 insertions. Since millions of bone marrow cells are modified and returned to the boys, such insertions may crop up in most if not all of the patients.

The added gene has now turned up near Lmo2 in a third child in the French trial, von Kalle last week told a gene therapy conference in Banff, Canada. Fortunately, the boy shows no signs of leukaemia, suggesting that a further genetic defect may be necessary to trigger uncontrolled growth of the modified cells.

Gene therapists are still hoping that this problem will prove specific to the gene or methods used in the X-SCID therapy. But experiments done by Frederic Bushman of the Salk Institute near San Diego suggests there could also be a potential problem with HIV and other related retroviruses, which many researchers are planning to use in gene therapy.

Bushman infected human cells with the viruses and looked to see where they landed. Last year, he reported that the viruses are more likely to land in genes- especially in active on
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
12-Mar-2003


Page: 1 2

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer risk clouds gene cures

(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a ... announced that its U.are.U ® 4500 fingerprint ... Eateries, Inc., a San ... chain, to increase security, improve accountability and reduce ... enable instant, non-repudiable identity confirmation for employee sign ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
Cached News: